How microbiota improve immunotherapy
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Ligands derived from the gut microbiota enhance cancer immunotherapy Animals have coevolved with complex communities of microorganisms living on barrier tissues, referred to as the microbiota or commensals. The microbiota controls immune function not only locally within barrier tissues but also systemically, modulating functions such as hematopoiesis, immune system development, and responses to vaccines (1). The role of the microbiota in enhancing responses to cancer immunotherapy has represented a major focus of research (2–7), although the mechanisms have remained largely unclear. On page 1040 of this issue, Griffin et al. (8) show that members of the Enterococcus genus promote immunotherapy responses in mice through immunostimulatory muropeptides, which are structural units of bacterial cell walls.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Therapeutic strategies involving the manipulation of gut microbiota to enhance ICI efficacy also include adjusting diet and lifestyle, taking prebiotics, and avoiding antibiotics [155–158].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [156]
Citations
Cites
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107
Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients
Davar, D., Dzutsev, A. K., McCulloch, J. A., Rodrigues, R. R., Chauvin, J.-M., Morrison, R. M., Deblasio, R. N., Menna, C., Ding, Q., Pagliano, O., et al. (2021) · Science · doi:10.1126/science.abf3363 · Cited by 1,781
Self-citationFecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
Baruch, E. N., Youngster, I., Ben-Betzalel, G., Ortenberg, R., Lahat, A., Katz, L., Adler, K., Dick-Necula, D., Raskin, S., Bloch, N., et al. (2021) · Science · doi:10.1126/science.abb5920 · Cited by 1,757
Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy
Mager, L. F., Burkhard, R., Pett, N., Cooke, N. C. A., Brown, K., Ramay, H., Paik, S., Stagg, J., Groves, R. A., Gallo, M., et al. (2020) · Science · doi:10.1126/science.abc3421 · Cited by 1,407
The microbiome and human cancer
Sepich-Poore, G. D., Zitvogel, L., Straussman, R., Hasty, J., Wargo, J. A., & Knight, R. (2021) · Science · doi:10.1126/science.abc4552 · Cited by 1,332
NOD1 and NOD2: Signaling, Host Defense, and Inflammatory Disease
Caruso, R., Warner, N., Inohara, N., & Núñez, G. (2014) · Immunity · doi:10.1016/j.immuni.2014.12.010 · Cited by 830
Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage
Fluckiger, A., Daillère, R., Sassi, M., Sixt, B. S., Liu, P., Loos, F., Richard, C., Rabu, C., Alou, M. T., Goubet, A.-G., et al. (2020) · Science · doi:10.1126/science.aax0701 · Cited by 396
Cited by
Hallmarks of Cancer: New Dimensions
Hanahan, D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1059 · Cited by 9,887
Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies
(2022) · doi:10.1186/s13045-022-01273-9 · Cited by 495
Akkermansia muciniphila phospholipid induces homeostatic immune responses
Bae, M., Cassilly, C. D., Liu, X., Park, S.-M., Tusi, B. K., Chen, X., Kwon, J., Filipčík, P., Bolze, A. S., Liu, Z., et al. (2022) · Nature · doi:10.1038/s41586-022-04985-7 · Cited by 413
Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer
Wang, X., Fang, Y., Liang, W., Wong, C. C., Qin, H., Gao, Y., Liang, M., Song, L., Zhang, Y., Fan, M., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.08.019 · Cited by 247
Dietary Lactobacillus -Derived Exopolysaccharide Enhances Immune-Checkpoint Blockade Therapy
Kawanabe-Matsuda, H., Takeda, K., Nakamura, M., Makino, S., Karasaki, T., Kakimi, K., Nishimukai, M., Ohno, T., Omi, J., Kano, K., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0929 · Cited by 150
Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
Simpson, R. C., Shanahan, E. R., Scolyer, R. A., & Long, G. V. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00803-9 · Cited by 153
Regulatory T cells in the face of the intestinal microbiota
Ramanan, D., Pratama, A., Zhu, Y., Venezia, O., Sassone-Corsi, M., Chowdhary, K., Galván-Peña, S., Sefik, E., Brown, C., Gélineau, A., et al. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00890-w · Cited by 126
“…cells (at least in a non-inflammatory context) 25 , A. muciniphila drives T follicular helper cell-like conventional T cells more than T reg cells 101 , commensal Cryptosporidia induce either T H 1 cells or T reg cells depending on the presence of dendritic cells 104 , whereas an epitope from…”
BackgroundDysbiosis of skin microbiome and gut microbiome in melanoma progression
Mekadim, C., Skalnikova, H. K., Cizkova, J., Cizkova, V., Palanova, A., Horak, V., & Mrazek, J. (2022) · BMC Microbiology · doi:10.1186/s12866-022-02458-5 · Cited by 93
Han, G., & Vaishnava, S. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01120-y · Cited by 86
Modulating brain function with microbiota
Foster, J. A. (2022) · Science · doi:10.1126/science.abo4220 · Cited by 53
Hamade, D. F., Espinal, A., Yu, J., Leibowitz, B. J., Fisher, R., Hou, W., Shields, D., van Pijkeren, J.-P., Mukherjee, A., Epperly, M. W., et al. (2022) · Radiation Research · doi:10.1667/rade-21-00224.1 · Cited by 36
Cell membrane-coated nanoparticles for targeting carcinogenic bacteria
Sun, L., Wang, D., Feng, K., Zhang, J. A., Gao, W., & Zhang, L. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115320 · Cited by 34
Merali, N., Chouari, T. A. M., Kayani, K., Rayner, C. J., Jiménez, J. I., Krell, J., Giovannetti, E., Bagwan, I., Relph, K., Rockall, T., et al. (2022) · Cancers · doi:10.3390/cancers14041020 · Cited by 29
Redrawing therapeutic boundaries: microbiota and cancer
Sholl, J., Sepich‐Poore, G. D., Knight, R. D., & Pradeu, T. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.10.008 · Cited by 33
Precision Probiotic Medicine to Improve ICB Immunotherapy
Luccia, B. D., & Colonna, M. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0221 · Cited by 24
Molecules-mediated bidirectional interactions between microbes and human cells
Wu, S., Bu, X., Chen, D., Wu, X., Wu, H., Caiyin, Q., & Qiao, J. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00657-2 · Cited by 33
Hamade, D. F., Epperly, M. W., Fisher, R., Hou, W., Shields, D. S., van Pijkeren, J., Mukherjee, A., Yu, J., Leibowitz, B. J., Vlad, A., et al. (2023) · Cancers · doi:10.3390/cancers15061670 · Cited by 23
Duan, J., Pan, J., Sun, M., & Fang, Y. (2022) · Food Research International · doi:10.1016/j.foodres.2022.111819 · Cited by 18
Huang, W., Jin, L., Yin, H., Tang, S., Yu, Y., & Yang, Y. (2023) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2023.164823 · Cited by 20
Metabolic heterogeneity in tumor microenvironment – A novel landmark for immunotherapy
Chen, C., Han, P., & Qing, Y. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103579 · Cited by 17
Du, P., Jing, J., & He, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1091124 · Cited by 15
Targeting microbiome, drug metabolism, and drug delivery in oncology
Sumiyoshi, A., Fujii, H., & Okuma, Y. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114902 · Cited by 9
Campillo-Gimenez, L., Ríos-Covián, D., Rivera–Nieves, J., Kiyono, H., Chu, H., & Ernst, P. B. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.752304 · Cited by 6
Cytokine release and NLRP3 inflammasome activation induced by low-abundance oral bacterial biofilms
Karched, M., Guleri, R. P., Al-Melh, M. A., & Qudeimat, M. A. (2025) · Journal of Oral Microbiology · doi:10.1080/20002297.2025.2552167 · Cited by 5
Potential of yeast probiotics as immunomodulators: a new frontier in cancer management
Mahooti, M., Safaei, F., Mousavian, Z., Samimiazad, A., Bakhtiyarizadeh, M., Emadi, A., Babae, L., Hassani, F. S., Eskandari, A., Azman, E. M., et al. (2026) · Future Microbiology · doi:10.1080/17460913.2026.2624283 · Cited by 2
Onco-biome in pharmacotherapy for lung cancer: a narrative review
Tateishi, A., & Okuma, Y. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-299 · Cited by 2
Hase, H., Takeda, Y., Koyama, S., Naito, Y., Jingushi, K., Fukada, S., & Tsujikawa, K. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1773700 · Cited by 1
Malignes Melanom und Adipositas: eine Übersichtsarbeit
Zidane, M., Theurich, S., & Schlaak, M. S. (2022) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-1849-6722
Malignes Melanom und Adipositas: eine Übersichtsarbeit
Zidane, M., Theurich, S., & Schlaak, M. S. (2023) · TumorDiagnostik & Therapie · doi:10.1055/a-2037-1458
Kawanabe-Matsuda, H., Takeda, K., Nakamura, M., Makino, S., Karasaki, T., Kakimi, K., Nishimukai, M., Ohno, T., Omi, J., Kano, K., et al. (2023) · doi:10.1158/2159-8290.c.6549610
Malignes Melanom und Adipositas: eine Übersichtsarbeit
Zidane, M., Theurich, S., & Schlaak, M. S. (2023) · Aktuelle Dermatologie · doi:10.1055/a-2086-2939
Ghannoum, M. A., Elshaer, M. Y. S., Al-Shakhshir, H., Retuerto, M., & McCormick, T. S. (2024) · Life · doi:10.3390/life14070824
Additional file 6 of Dysbiosis of skin microbiome and gut microbiome in melanoma progression
Mekadim, C., Skalníková, H. K., Cizkova, J., Cizkova, V., Palanová, A., Horák, V., & Mrazek, J. (2022) · Figshare · doi:10.6084/m9.figshare.19242139
Additional file 21 of Dysbiosis of skin microbiome and gut microbiome in melanoma progression
Mekadim, C., Skalníková, H. K., Cizkova, J., Cizkova, V., Palanová, A., Horák, V., & Mrazek, J. (2022) · Figshare · doi:10.6084/m9.figshare.19242076
Additional file 19 of Dysbiosis of skin microbiome and gut microbiome in melanoma progression
Mekadim, C., Skalníková, H. K., Cizkova, J., Cizkova, V., Palanová, A., Horák, V., & Mrazek, J. (2022) · Figshare · doi:10.6084/m9.figshare.19242058
Additional file 16 of Dysbiosis of skin microbiome and gut microbiome in melanoma progression
Mekadim, C., Skalníková, H. K., Cizkova, J., Cizkova, V., Palanová, A., Horák, V., & Mrazek, J. (2022) · Figshare · doi:10.6084/m9.figshare.19242040
Additional file 12 of Dysbiosis of skin microbiome and gut microbiome in melanoma progression
Mekadim, C., Skalníková, H. K., Cizkova, J., Cizkova, V., Palanová, A., Horák, V., & Mrazek, J. (2022) · Figshare · doi:10.6084/m9.figshare.19242022
Additional file 3 of Dysbiosis of skin microbiome and gut microbiome in melanoma progression
Mekadim, C., Skalníková, H. K., Cizkova, J., Cizkova, V., Palanová, A., Horák, V., & Mrazek, J. (2022) · Figshare · doi:10.6084/m9.figshare.19242118
Additional file 17 of Dysbiosis of skin microbiome and gut microbiome in melanoma progression
Mekadim, C., Skalníková, H. K., Cizkova, J., Cizkova, V., Palanová, A., Horák, V., & Mrazek, J. (2022) · Figshare · doi:10.6084/m9.figshare.19242046
Additional file 18 of Dysbiosis of skin microbiome and gut microbiome in melanoma progression
Mekadim, C., Skalníková, H. K., Cizkova, J., Cizkova, V., Palanová, A., Horák, V., & Mrazek, J. (2022) · Figshare · doi:10.6084/m9.figshare.19242052
Additional file 15 of Dysbiosis of skin microbiome and gut microbiome in melanoma progression
Mekadim, C., Skalníková, H. K., Cizkova, J., Cizkova, V., Palanová, A., Horák, V., & Mrazek, J. (2022) · Figshare · doi:10.6084/m9.figshare.19242037
Additional file 14 of Dysbiosis of skin microbiome and gut microbiome in melanoma progression
Mekadim, C., Skalníková, H. K., Cizkova, J., Cizkova, V., Palanová, A., Horák, V., & Mrázek, J. (2022) · Figshare · doi:10.6084/m9.figshare.19242031
Additional file 4 of Dysbiosis of skin microbiome and gut microbiome in melanoma progression
Mekadim, C., Skalníková, H. K., Cizkova, J., Cizkova, V., Palanová, A., Horák, V., & Mrazek, J. (2022) · Figshare · doi:10.6084/m9.figshare.19242124
Additional file 13 of Dysbiosis of skin microbiome and gut microbiome in melanoma progression
Mekadim, C., Skalníková, H. K., Cizkova, J., Cizkova, V., Palanová, A., Horák, V., & Mrazek, J. (2022) · Figshare · doi:10.6084/m9.figshare.19242028
Additional file 1 of Dysbiosis of skin microbiome and gut microbiome in melanoma progression
Mekadim, C., Skalníková, H. K., Cizkova, J., Cizkova, V., Palanová, A., Horák, V., & Mrazek, J. (2022) · Figshare · doi:10.6084/m9.figshare.19242064
Additional file 7 of Dysbiosis of skin microbiome and gut microbiome in melanoma progression
Mekadim, C., Skalníková, H. K., Cizkova, J., Cizkova, V., Palanová, A., Horák, V., & Mrazek, J. (2022) · Figshare · doi:10.6084/m9.figshare.19242142
Additional file 8 of Dysbiosis of skin microbiome and gut microbiome in melanoma progression
Mekadim, C., Skalníková, H. K., Cizkova, J., Cizkova, V., Palanová, A., Horák, V., & Mrazek, J. (2022) · Figshare · doi:10.6084/m9.figshare.19242145
Additional file 2 of Dysbiosis of skin microbiome and gut microbiome in melanoma progression
Mekadim, C., Skalníková, H. K., Cizkova, J., Cizkova, V., Palanová, A., Horák, V., & Mrazek, J. (2022) · Figshare · doi:10.6084/m9.figshare.19242112
Additional file 10 of Dysbiosis of skin microbiome and gut microbiome in melanoma progression
Mekadim, C., Skalníková, H. K., Cizkova, J., Cizkova, V., Palanová, A., Horák, V., & Mrázek, J. (2022) · Figshare · doi:10.6084/m9.figshare.19242013
Additional file 20 of Dysbiosis of skin microbiome and gut microbiome in melanoma progression
Mekadim, C., Skalníková, H. K., Cizkova, J., Cizkova, V., Palanová, A., Horák, V., & Mrazek, J. (2022) · Figshare · doi:10.6084/m9.figshare.19242070
Additional file 5 of Dysbiosis of skin microbiome and gut microbiome in melanoma progression
Mekadim, C., Skalníková, H. K., Cizkova, J., Cizkova, V., Palanová, A., Horák, V., & Mrazek, J. (2022) · Figshare · doi:10.6084/m9.figshare.19242133
Additional file 11 of Dysbiosis of skin microbiome and gut microbiome in melanoma progression
Mekadim, C., Skalníková, H. K., Cizkova, J., Cizkova, V., Palanová, A., Horák, V., & Mrazek, J. (2022) · Figshare · doi:10.6084/m9.figshare.19242016
Additional file 9 of Dysbiosis of skin microbiome and gut microbiome in melanoma progression
Mekadim, C., Skalníková, H. K., Cizkova, J., Cizkova, V., Palanová, A., Horák, V., & Mrazek, J. (2022) · Figshare · doi:10.6084/m9.figshare.19242151
Identification and Evaluation of Benzimidazole- Agonists of Innate Immune Receptor NOD2
Wittle, L. E., Ocius, K. L., Chordia, M. D., Wagoner, C. M. V., Bullock, T. N. J., & Pires, M. M. (2026) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5c00737
Metadata
- Authors
- Ansaldo, E., & Belkaid, Y.
- Affiliations
- National Institutes of Health (US)
- Venue
- Science
- Published
- 2021-08-27
- Volume
- 373
- Issue
- 6558
- Pages
- 966-967
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W3194146144
- Cited by
- 54
- References
- 15
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 4 · 2023: 9 · 2022: 34 · 2021: 2
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- gut microbiota, cancer immunotherapy, host-microbe interactions
- MeSH terms
- Immunotherapy, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.